Prevalence of Stenotrophomonas maltophilia in Cancer Patients at a tertiary care hospital

maltophilia is an environmental bacterium, which poses an upcoming threat to Immune suppressed individuals globally. An emerging resistance to Cotrimoxazole (drug of choice), is a serious concern in clinical practice. The aim of the study was to determine the prevalence of S. maltophilia in cancer patients at a tertiary care hospital. This retrospective study was conducted from microbiological data collected from January 2020 to December 2021. Routine antimicrobial susceptibility testing to Cotrimoxazole, Levofloxacin, Ceftazidime and Minocycline was also performed. A total of 181 isolates of S maltophilia were studied. 64.4% were males and in all individuals with more than 45 years of age were most affected. It was most susceptible to Minocycline (96.7 %) and least susceptible to Cotrimoxazole (61.9%). S. maltophilia is an emerging global opportunistic pathogen in cancer patients with limited treatment options.